Targeted Metabolomics Analysis Suggests ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Title :
Targeted Metabolomics Analysis Suggests That Tacrolimus Alters Protection against Oxidative Stress.
Author(s) :
Joncquel, M. [Auteur]
Labasque, J. [Auteur]
Demaret, J. [Auteur]
Bout, M. A. [Auteur]
Hamroun, Aghiles [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Hennart, Benjamin [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Tronchon, M. [Auteur]
Defevre, M. [Auteur]
Kim, I. [Auteur]
Kerckhove, A. [Auteur]
George, L. [Auteur]
Gilleron, M. [Auteur]
Dessein, A. F. [Auteur]
Zerimech, Farid [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Grzych, G. [Auteur]
Labasque, J. [Auteur]
Demaret, J. [Auteur]
Bout, M. A. [Auteur]
Hamroun, Aghiles [Auteur]
Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE]
Hennart, Benjamin [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Tronchon, M. [Auteur]
Defevre, M. [Auteur]
Kim, I. [Auteur]
Kerckhove, A. [Auteur]
George, L. [Auteur]
Gilleron, M. [Auteur]
Dessein, A. F. [Auteur]
Zerimech, Farid [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Grzych, G. [Auteur]
Journal title :
Antioxidants
Pages :
1412
Publisher :
MDPI
Publication date :
2023-07-12
ISSN :
2076-3921
English keyword(s) :
pipecolic acid
immunosuppressive
tacrolimus
metabolomics
oxidative stress
immunosuppressive
tacrolimus
metabolomics
oxidative stress
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
settingsOrder Article ReprintsOpen AccessArticleTargeted Metabolomics Analysis Suggests That Tacrolimus Alters Protection against Oxidative Stressby Marie Joncquel1 [ORCID] , Julie Labasque1, Julie Demaret2 [ORCID] , ...
Show more >settingsOrder Article ReprintsOpen AccessArticleTargeted Metabolomics Analysis Suggests That Tacrolimus Alters Protection against Oxidative Stressby Marie Joncquel1 [ORCID] , Julie Labasque1, Julie Demaret2 [ORCID] , Marie-Adélaïde Bout1, Aghilès Hamroun3, Benjamin Hennart4, Mathieu Tronchon2, Magali Defevre1, Isabelle Kim1, Alain Kerckhove1, Laurence George1, Mylène Gilleron1, Anne-Frédérique Dessein1, Farid Zerimech1,5 [ORCID] and Guillaume Grzych1,*1CHU Lille, Centre de Biologie Pathologie Génétique, Service Hormonologie Métabolisme Nutrition Oncologie, F-59000 Lille, France2CHU Lille, Centre de Biologie Pathologie Génétique, Institut d’Immunologie, F-59000 Lille, France3UMR1167 RIDAGE, Institut Pasteur de Lille, Inserm, Université de Lille, CHU Lille, F-59000 Lille, France4CHU Lille, Centre de Biologie Pathologie Génétique, Service Toxicologie et Génopathies, F-59000 Lille, France5Institut Pasteur de Lille, Université de Lille, ULR 4483, IMPECS, F-59000 Lille, France*Author to whom correspondence should be addressed.Antioxidants 2023, 12(7), 1412; https://doi.org/10.3390/antiox12071412Submission received: 23 June 2023 / Revised: 6 July 2023 / Accepted: 11 July 2023 / Published: 12 July 2023(This article belongs to the Special Issue Redox Biomarkers in Dietary Interventions and Nutritional Observation Studies)Downloadkeyboard_arrow_downBrowse FiguresReview Reports Versions NotesAbstractTacrolimus (FK506) is an immunosuppressant that is experiencing a continuous rise in usage worldwide. The related side effects are known to be globally dose-dependent. Despite numerous studies on FK506, the mechanisms underlying FK506 toxicity are still not well understood. It is therefore essential to explore the toxicity mediated by FK506. To accomplish this, we conducted a targeted metabolomic analysis using LC−MS on the plasma samples of patients undergoing FK506 treatment. The aim was to identify any associated altered metabolic pathway. Another anti-calcineurin immunosuppressive therapy, ciclosporin (CSA), was also studied. Increased plasma concentrations of pipecolic acid (PA) and sarcosine, along with a decrease in the glycine/sarcosine ratio and a tendency of increased plasma lysine was observed in patients under FK506 compared to control samples. Patients under CSA do not show an increase in plasma PA compared to the control samples, which does not support a metabolic link between the calcineurin and PA. The metabolomics changes observed in patients under FK506 highlight a possible link between FK506 and the action of an enzyme involved in both PA and sarcosine catabolism and oxidative pathway, the Peroxisomal sarcosine oxidase (PIPOX). Moreover, PA could be investigated as a potential biomarker of early nephrotoxicity in the follow-up of patients under FK506.Show less >
Show more >settingsOrder Article ReprintsOpen AccessArticleTargeted Metabolomics Analysis Suggests That Tacrolimus Alters Protection against Oxidative Stressby Marie Joncquel1 [ORCID] , Julie Labasque1, Julie Demaret2 [ORCID] , Marie-Adélaïde Bout1, Aghilès Hamroun3, Benjamin Hennart4, Mathieu Tronchon2, Magali Defevre1, Isabelle Kim1, Alain Kerckhove1, Laurence George1, Mylène Gilleron1, Anne-Frédérique Dessein1, Farid Zerimech1,5 [ORCID] and Guillaume Grzych1,*1CHU Lille, Centre de Biologie Pathologie Génétique, Service Hormonologie Métabolisme Nutrition Oncologie, F-59000 Lille, France2CHU Lille, Centre de Biologie Pathologie Génétique, Institut d’Immunologie, F-59000 Lille, France3UMR1167 RIDAGE, Institut Pasteur de Lille, Inserm, Université de Lille, CHU Lille, F-59000 Lille, France4CHU Lille, Centre de Biologie Pathologie Génétique, Service Toxicologie et Génopathies, F-59000 Lille, France5Institut Pasteur de Lille, Université de Lille, ULR 4483, IMPECS, F-59000 Lille, France*Author to whom correspondence should be addressed.Antioxidants 2023, 12(7), 1412; https://doi.org/10.3390/antiox12071412Submission received: 23 June 2023 / Revised: 6 July 2023 / Accepted: 11 July 2023 / Published: 12 July 2023(This article belongs to the Special Issue Redox Biomarkers in Dietary Interventions and Nutritional Observation Studies)Downloadkeyboard_arrow_downBrowse FiguresReview Reports Versions NotesAbstractTacrolimus (FK506) is an immunosuppressant that is experiencing a continuous rise in usage worldwide. The related side effects are known to be globally dose-dependent. Despite numerous studies on FK506, the mechanisms underlying FK506 toxicity are still not well understood. It is therefore essential to explore the toxicity mediated by FK506. To accomplish this, we conducted a targeted metabolomic analysis using LC−MS on the plasma samples of patients undergoing FK506 treatment. The aim was to identify any associated altered metabolic pathway. Another anti-calcineurin immunosuppressive therapy, ciclosporin (CSA), was also studied. Increased plasma concentrations of pipecolic acid (PA) and sarcosine, along with a decrease in the glycine/sarcosine ratio and a tendency of increased plasma lysine was observed in patients under FK506 compared to control samples. Patients under CSA do not show an increase in plasma PA compared to the control samples, which does not support a metabolic link between the calcineurin and PA. The metabolomics changes observed in patients under FK506 highlight a possible link between FK506 and the action of an enzyme involved in both PA and sarcosine catabolism and oxidative pathway, the Peroxisomal sarcosine oxidase (PIPOX). Moreover, PA could be investigated as a potential biomarker of early nephrotoxicity in the follow-up of patients under FK506.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Collections :
Source :
Files
- document
- Open access
- Access the document
- Joncquel%20et%20al.pdf
- Open access
- Access the document
- document
- Open access
- Access the document
- Joncquel%20et%20al.pdf
- Open access
- Access the document